Product Launch
Absci’s ABS-201 shows 65-day half-life in alopecia trial
June 24, 2026
Biotech
Product Launch
Key Facts
Signal Type
Product Launch
Industry
Biotech
Companies
Absci
Date
June 24, 2026
Absci reported positive interim Phase 1 data from its HEADLINE trial of ABS-201, an investigational anti-PRLR antibody. The drug showed a 65-day half-life and favorable safety profile across four dose cohorts (150-1800 mg IV) in healthy volunteers.
This development primarily impacts biopharma companies competing in alopecia and endometriosis therapeutics. Clinical teams at Absci are advancing to multiple ascending dose studies in androgenetic alopecia patients, with data expected H2 2026.
Key milestones include interim proof-of-concept data in H2 2026 and full data in early 2027. The planned Phase 2 endometriosis trial later this year could further validate ABS-201's platform potential.
Source:
Stock TitanGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
